Levetiracetam Tablet, Film Coated
Product Images NDC 71335-2098

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 71335-2098). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (E24dd8a7 86c4 4979 8f2e Da2d82f5d6d8 01)

This text provides a formula to calculate the total daily dose of a medication based on the patient's weight and the daily dose in milligrams per kilogram. The medication's concentration is also given as 100 mg/mL.*

FDA Label Image

Figure 2 (E24dd8a7 86c4 4979 8f2e Da2d82f5d6d8 02)

FDA Label Image

Structure (E24dd8a7 86c4 4979 8f2e Da2d82f5d6d8 03)

FDA Label Image

Figure 4 (E24dd8a7 86c4 4979 8f2e Da2d82f5d6d8 04)

FDA Label Image

Figure 5 (E24dd8a7 86c4 4979 8f2e Da2d82f5d6d8 05)

This appears to be a table showing the percentage of patients with different levels of response in a study comparing the effectiveness of a placebo to two different doses of a medication called Levetiracetam. The percentages shown represent the proportion of patients in each group who had a particular level of response. However, without additional context or headings, it is difficult to say exactly what these levels of response represent.*

FDA Label Image

Figure 6 (E24dd8a7 86c4 4979 8f2e Da2d82f5d6d8 06)

FDA Label Image

Figure 7 (E24dd8a7 86c4 4979 8f2e Da2d82f5d6d8 07)

This appears to be a chart displaying percentages of different categories of patients who received either a placebo or Levetiracetam in a study. However, without more information it is difficult to discern the exact meaning and context of the percentages.*

FDA Label Image

Figure 8 (E24dd8a7 86c4 4979 8f2e Da2d82f5d6d8 08)

This is a comparison of two groups of patients who were given either a placebo or levetiracetam. The percentages indicate the proportion of patients who responded positively to the treatments, with 19.6% responding positively to the placebo and 43.1% responding positively to levetiracetam. The sample sizes for each group are also provided (N=51 for the placebo group and N=58 for the levetiracetam group).*

FDA Label Image

Figure 9 (E24dd8a7 86c4 4979 8f2e Da2d82f5d6d8 09)

This appears to be a chart that shows the percentage of patients who experienced certain outcomes (represented on the y-axis) while taking a placebo or levetiracetam (represented on the x-axis). The outcomes are not described and there is no context provided to understand what the percentages represent.*

FDA Label Image

Label (Lbl713352098)

This appears to be a label for a medication package. The medication is likely a 750mg tablet of Keppra, produced by Lupin Limited. The package contains 30 tablets and should be stored at room temperature. The NDC number provided is 7133520981. The label also includes a disclaimer to keep all drugs out of reach of children.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.